In Guilty Plea, OxyContin Maker to Pay $600 Million #medicinal #chemistry

Posted On Sep 24 2017 by

#purdue pharmaceutical # The New York Times In Guilty Plea, OxyContin Maker to Pay $600 Million From left, Howard R. Udell, the top lawyer for Purdue Pharma; Dr. Paul D. Goldenheim, the company s former medical director; and Michael Friedman, Purdue s president. Photographs by Don Petersen for The New York Times May 10, 2007 ABINGDON, Va. May 10 — The company that makes the narcotic painkiller OxyContin and three current and former executives pleaded guilty today in federal court here to criminal charges that they misled regulators, doctors and patients about the drug’s risk of addiction and its potential …


In Guilty Plea, OxyContin Maker to Pay $600 Million #martindale #pharma

Posted On Mar 14 2017 by

#purdue pharmaceutical # The New York Times In Guilty Plea, OxyContin Maker to Pay $600 Million From left, Howard R. Udell, the top lawyer for Purdue Pharma; Dr. Paul D. Goldenheim, the company s former medical director; and Michael Friedman, Purdue s president. Photographs by Don Petersen for The New York Times May 10, 2007 ABINGDON, Va. May 10 — The company that makes the narcotic painkiller OxyContin and three current and former executives pleaded guilty today in federal court here to criminal charges that they misled regulators, doctors and patients about the drug’s risk of addiction and its potential …


In Guilty Plea, OxyContin Maker to Pay $600 Million #astellas #pharma #europe

Posted On Nov 10 2016 by

#purdue pharmaceutical # The New York Times In Guilty Plea, OxyContin Maker to Pay $600 Million From left, Howard R. Udell, the top lawyer for Purdue Pharma; Dr. Paul D. Goldenheim, the company s former medical director; and Michael Friedman, Purdue s president. Photographs by Don Petersen for The New York Times May 10, 2007 ABINGDON, Va. May 10 — The company that makes the narcotic painkiller OxyContin and three current and former executives pleaded guilty today in federal court here to criminal charges that they misled regulators, doctors and patients about the drug’s risk of addiction and its potential …